O4386
L-Ornithine monohydrochloride
≥99%, BioXtra
동의어(들):
(S)-2,5-Diaminopentanoic acid monohydrochloride
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C5H12N2O2 · HCl
CAS 번호:
Molecular Weight:
168.62
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-678-6
MDL number:
Beilstein/REAXYS Number:
3625847
제품 이름
L-Ornithine monohydrochloride, BioXtra, ≥99%
product line
BioXtra
Quality Level
assay
≥99%
form
powder
impurities
ammonia- and citrulline-free, essentially free, ≤0.005% Phosphorus (P), ≤0.1% Insoluble matter
ign. residue
≤0.1%
color
white
solubility
H2O: 1 M at 20 °C, clear, faintly yellow
anion traces
sulfate (SO42-): ≤0.05%
cation traces
Al: ≤0.0005%, Ca: ≤0.005%, Cu: ≤0.0005%, Fe: ≤0.0005%, K: ≤0.005%, Mg: ≤0.0005%, NH4+: ≤0.05%, Na: ≤0.005%, Pb: ≤0.001%, Zn: ≤0.0005%
SMILES string
Cl.NCCC[C@H](N)C(O)=O
InChI
1S/C5H12N2O2.ClH/c6-3-1-2-4(7)5(8)9;/h4H,1-3,6-7H2,(H,8,9);1H/t4-;/m0./s1
InChI key
GGTYBZJRPHEQDG-WCCKRBBISA-N
Biochem/physiol Actions
L-Ornithine is a not encoded by DNA. It is a free amino acid but do not participate in the protein synthesis. It is formed by the action of the enzyme arginase on L-arginine in the process of forming urea. It is implicated in the reduction of blood ammonia level and improves the efficiency of energy production to cause ammonia detoxification. L-ornithine promotes the release of growth hormone by triggering the pituitary gland.
Other Notes
Product of arginine degradation by arginase
저장 등급
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
L-ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism
Sugino T, et al.
Nutrition Research (New York, N.Y.), 28(11), 738-743 (2008)
The effect of L-ornithine hydrochloride ingestion on performance during incremental exhaustive ergometer bicycle exercise and ammonia metabolism during and after exercise
Demura S, et al.
European Journal of Clinical Nutrition, 64(10), 1166-1171 (2010)
Sherry Dadsetan et al.
Biochemical pharmacology, 85(1), 115-123 (2012-10-30)
Combined administration of ornithine and phenylacetate (OP) is proposed as a novel treatment of hyperammonemia and hepatic encephalopathy. Ornithine is believed to increase ammonia fixation into glutamine in muscle tissue and glutamine is subsequently thought to react with phenylacetate forming